About the Company
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group. Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on TITAN PHARMACEUTICALS INC
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
--Titan Pharmaceuticals, Inc. today announced that it has entered into an Asset Purchase Agreement with Fedson, Inc., a Delaware Corporation, for the sale of certain ProNeura assets including ...
Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT ...
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura ® long-term, continuous drug ...
TTNPW Titan Pharmaceuticals, Inc. WT B EXP 101824
Titan Pharmaceuticals, Inc. WT B EXP 101824 (TTNPW) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS ...
Titan Pharmaceuticals Completes Private Placement of Series C ... - Nasdaq
Titan Pharmaceuticals, Inc. announced a private placement of its newly designated Series C Convertible Preferred Stock, selling 60,000 shares to Blue Harbour Asset Management for $600,000.
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with ...
SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (TTNP) ("Titan" or the "Company") today announced that it has granted an exclusive license to Ocular Therapeutix Inc ...
Titan Pharmaceuticals Announces $1 Million Private Placement of ...
NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities pur ...
Titan Pharmaceuticals Announces Submission of New Drug Application for ...
Titan Pharmaceuticals, Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational product Probuphine® for the maintenance ...
Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals ...
Provided by PR Newswire Aug 23, 2024 5:07pm Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders ...
Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 ...
Shares of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) rose sharply in today’s pre-market trading session. Titan Pharmaceuticals said its Board of Directors has approved a 1-for-20 reverse stock ...
Similar Companies
Loading the latest forecasts...